Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.
about
Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapyFifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudineBiological comparison of wild-type and zidovudine-resistant isolates of human immunodeficiency virus type 1 from the same subjects: susceptibility and resistance to other drugsDetection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridizationBI-RG-587 is active against zidovudine-resistant human immunodeficiency virus type 1 and synergistic with zidovudineZidovudine-resistant human immunodeficiency virus selected by passage in cell cultureSynergistic inhibition of human immunodeficiency virus type 1 replication in vitro by two-drug and three-drug combinations of 3'-azido-3'-deoxythymidine, phosphonoformate, and 2',3'-dideoxythymidineHuman immunodeficiency virus type 1 mutants resistant to nonnucleoside inhibitors of reverse transcriptase arise in tissue cultureMutants of feline immunodeficiency virus resistant to 3'-azido-3'-deoxythymidine3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsHuman immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2',3'-dideoxycytidineActivities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytesHigh-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptaseMutagenic study of codons 74 and 215 of the human immunodeficiency virus type 1 reverse transcriptase, which are significant in nucleoside analog resistancePreclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitroInfluence of stereochemistry on antiviral activities and resistance profiles of dideoxycytidine nucleosidesNovel mutation (V75T) in human immunodeficiency virus type 1 reverse transcriptase confers resistance to 2',3'-didehydro-2',3'-dideoxythymidine in cell culture5-Chloro-2',3'-dideoxy-3'-fluorouridine (935U83), a selective anti-human immunodeficiency virus agent with an improved metabolic and toxicological profileNovel mutations in reverse transcriptase of human immunodeficiency virus type 1 reduce susceptibility to foscarnet in laboratory and clinical isolatesCharacterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosidesRapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptasePhosphatidylazidothymidine and phosphatidyl-ddC: assessment of uptake in mouse lymphoid tissues and antiviral activities in human immunodeficiency virus-infected cells and in Rauscher leukemia virus-infected miceHuman immunodeficiency virus type 1 pol gene mutations in an AIDS patient treated with multiple antiretroviral drugsResistance of clinical isolates of human immunodeficiency virus to antiretroviral agentsEvaluation of synergy between carbovir and 3'-azido-2',3'-deoxythymidine for inhibition of human immunodeficiency virus type 1Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Wor1592U89, a novel carbocyclic nucleoside analog with potent, selective anti-human immunodeficiency virus activityCombination of mutations in human immunodeficiency virus type 1 reverse transcriptase required for resistance to the carbocyclic nucleoside 1592U89Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityInhibition of hepatitis B virus by a novel L-nucleoside, 2'-fluoro-5-methyl-beta-L-arabinofuranosyl uracilA novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineMetabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine and its activity in combination with clinically approved anti-human immunodeficiency virus beta-D(+) nucleoside analogs in vitroDideoxynucleoside resistance emerges with prolonged zidovudine monotherapy. The RV43 Study Group.Rapid and simple phenotypic assay for drug susceptibility of human immunodeficiency virus type 1 using CCR5-expressing HeLa/CD4(+) cell clone 1-10 (MAGIC-5)Susceptibility of the human retrovirus XMRV to antiretroviral inhibitors.Antiviral, metabolic, and pharmacokinetic properties of the isomeric dideoxynucleoside 4(S)-(6-amino-9H-purin-9-yl)tetrahydro-2(S)-furanmethanol.Emergence of mutant HIV reverse transcriptase conferring resistance to AZT.Structures of reverse transcriptase pre- and post-excision complexes shed new light on HIV-1 AZT resistanceAntiretroviral therapy: reverse transcriptase inhibition.Kinetics of virus production from single cells
P2860
Q24684152-9EDD4687-E458-4EDC-A80C-02F9B67DF3C5Q28316118-E1DCD19D-EF03-46FA-A7A2-55BCDAAAE092Q28321397-E6D2E9F8-F5DB-434B-B178-FB94C18B57C9Q28323773-020EF393-E379-437D-99B3-9D5D37E909DEQ28323825-94B465BA-7DE7-4585-8428-857A5AF7A8A3Q28324074-0A1453C5-7100-484A-AC1C-C91A2F3F792DQ28324208-66FB7387-FB70-4A03-B271-24C5FD0B5F15Q28324214-9304A3B1-65CF-411A-A046-A113B8D0902AQ28326866-FFB4CD3C-F9B9-461C-B235-91C429A33B5BQ28342745-EC43167B-9C1F-402A-87A1-E94615E3D3BDQ28343184-53F397DD-CF89-4788-AEE1-66FE1CFA360BQ28343244-33780A5D-AF00-43CC-8681-B73BE7D63617Q28367493-17E8EC13-1D04-4D38-97B6-5E86F7BFC127Q28367539-8B116D40-9617-424C-9B07-D3C723DA53D9Q28367573-59A12A75-B9C8-4068-AB4F-3BA7C3AC8ADAQ28367580-D73FA7BE-9BFC-4FF2-A7AF-DB3C17C11402Q28367594-849DFD16-DC5C-4755-A4DD-35605A2905ADQ28367605-1E17194D-50D5-41E0-8BBD-6586E96D85C0Q28367722-D6788734-CBB8-4F7E-A5D2-A281F822E89EQ28368026-83231BB4-20F6-4E4F-9121-2C76F3959BDDQ28368030-A728C547-0DD1-4C4F-9A49-9FABBE189788Q28368058-5A23E775-1D82-447C-970A-8629003F692AQ28378322-577C0663-589A-49E1-8042-187A6CF13861Q28378547-DD988F2E-1781-4911-AE00-348C04E45496Q28378655-12F38552-6B60-4DE3-BFBB-359CF7AA0704Q28378727-3FB7231B-AADB-4195-8D27-B433FEE5CD15Q28378894-F3DD4986-38C5-49BE-BEB2-E539D5DF7EE5Q28378896-A8E09F15-CD3F-4934-A740-1BBF81A3046CQ28378951-3908748B-2CAF-43DA-9B97-975987288782Q28379171-2E6D22E3-DA37-45DF-888B-0F4BC651192FQ28379499-8860D8CE-D5A9-4055-9B84-48E031195FDEQ28379621-0B49884B-0F41-4375-9EB2-1B3088FC2A56Q33749177-474F8EE4-98E3-4E35-8D52-1D49F4237B99Q33981401-BF7A1319-F26D-4914-A366-80BEDA24CD23Q34128479-3B383A05-DDA2-42C7-B5B3-A2CAF661FAA7Q35118261-C165FA9E-0B36-4189-AE43-FA9A070D911EQ35174378-EA95A596-1712-4331-85E1-9C50CFA98FECQ35258630-AD3CFC0F-E526-4E9B-B62C-FBB66C7036ADQ35322871-6465B3EA-EB16-4230-ABDA-D29643A8B243Q35713464-156B6E49-A306-47EC-A5EF-47A1E33AFA59
P2860
Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.
description
1990 nî lūn-bûn
@nan
1990 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1990 թվականի մարտին հրատարակված գիտական հոդված
@hy
1990年の論文
@ja
1990年論文
@yue
1990年論文
@zh-hant
1990年論文
@zh-hk
1990年論文
@zh-mo
1990年論文
@zh-tw
1990年论文
@wuu
name
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@ast
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@en
type
label
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@ast
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@en
prefLabel
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@ast
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@en
P2093
P2860
P356
P1476
Susceptibilities of zidovudine ...... tative plaque reduction assay.
@en
P2093
B A Larder
B Chesebro
D D Richman
P2860
P304
P356
10.1128/AAC.34.3.436
P407
P577
1990-03-01T00:00:00Z